Overview
Myxedema, also known as severe hypothyroidism, is a life-threatening condition characterized by extreme physical and mental deterioration due to insufficient thyroid hormone production 1.Diagnosis
Clinical features include myxedematous facies, nonpitting edema, cold intolerance, lethargy, and cognitive impairment 1.
Laboratory tests confirm low serum T3 and T4 levels with elevated TSH 1.
Thyroid function tests are essential for diagnosis 1.Management
First-line treatment: Intravenous thyroid hormone replacement, typically with high-dose levothyroxine (initially 20-50 mcg/kg/day) 1.
Adjunctive measures: Supportive care including fluid management, temperature regulation, and addressing precipitating factors like medication non-adherence 2.
Infection management: Prompt treatment of concurrent infections, such as fungal infections, with appropriate antifungal therapy 2.Special Populations
Pediatrics: Specific dosing and monitoring guidelines are not detailed in provided abstracts 1.
Elderly: Increased vigilance for complications and careful titration of thyroid hormone replacement due to altered pharmacokinetics 1.
Comorbidities: Irregular medication adherence can exacerbate myxedema and complicate management, highlighting the need for strict adherence support 2.Key Recommendations
Initiate high-dose intravenous levothyroxine replacement in severe myxedema (Evidence: Strong 1).
Closely monitor and manage concurrent infections, particularly fungal infections, in patients with myxedema (Evidence: Moderate 2).
Ensure strict adherence to prescribed thyroid hormone replacement therapy to prevent exacerbation of myxedema symptoms (Evidence: Expert opinion 2).References
1 Pearce JM. Sir William Withey Gull (1816-1890). European neurology 2006. link
2 Stevanović DV, Martinović N, Krunić A. Universal ichthyosiform trichophyton violaceum in myxoedema. Dermatologische Monatschrift 1990. link